

Table S1.

PATIENT	PREVIOUS TREATMENT	FIBROSIS DEGREE	SUBTYPING (HRCS)	TREATMENT	RIBAVIRIN	VIRAL LOAD	TREATMENT DURATION (WEEKS)	TREATMENT END TO SAMPLE COLLECTION (WEEKS)
Pt 001	NO	Unknown	1a	SMV + SOF	NO	2.48E+06	Unknown	n.d.
Pt 002	Unknown	Unknown	4d	SMV + DCV	NO	1.10E+06	Unknown	n.d.
Pt 003	NO	F4	1b	SMV + SOF	YES	1.15E+07	24	7.14
Pt 004	NO	F4	4d	LDV + SOF	YES	7.30E+05	12	n.d.
Pt 005	NO	F4	1b	SMV + SOF	YES	1.70E+06	12	31.14
Pt 006	n.d.	F4	3a	SOF	YES	3.60E+05	24	19.29
Pt 007	n.d.	F3	1b	SMV + SOF	NO	2.33E+06	n.d.	n.d.
Pt 008	n.d.	F3	1b	FDV + DLV	NO	2.07E+05	n.d.	n.d.
Pt 009	NO	F3	1b	LDV + SOF	NO	8.48E+05	12	3.86
Pt 010	n.d.	n.d.	3a	SOF	YES	2.50E+05	24	n.d.
Pt 011	n.d.	F4	1b	LDV + SOF	NO	1.46E+06	12	n.d.
Pt 012	NO	F4	1b	LDV + SOF	NO	2.09E+06	24	n.d.
Pt 013	YES (PEG + TPV)	F4	1b	LDV + SOF	NO	1.10E+06	24	n.d.
Pt 014	NO	F3	1a	PTV/r + OMV + DSV	YES	8.80E+06	12	13.29
Pt 015	NO	F4	1b	SMV + SOF	YES	6.35E+06	12	57.43
Pt 016	n.d.	F3	1b	LDV + SOF	NO	4.37E+06	12	n.d.
Pt 017	NO	F4	1b	PTV/r + OMV + DSV	YES	1.05E+06	12	30.86
Pt 018	NO	F3	1b	PTV/r + OMV + DSV	NO	7.53E+05	12	31.57
Pt 019	YES (PegIFN + TPV + RBV)	F4	1b	LDV + SOF	YES	1.59E+06	12	18.14
Pt 020	Unknown	Unknown	3a	PTV/r + OMV + DSV	NO	1.20E+05	Unknown	n.d.
Pt 021	n.d.	F4	1b	LDV + SOF	NO	5.46E+06	n.d.	n.d.
Pt 022	n.d.	F4	3a	SOF + PegINF	YES	1.77E+05	12	n.d.
Pt 023	NO	F2	3a	DCV + SOF	NO	6.60E+06	12	n.d.
Pt 024	NO	F2	1a	LDV + SOF	NO	4.90E+06	12	n.d.
Pt 025	n.d.	n.d.	3a	DCV + SOF	NO	n.d.	24	n.d.
Pt 026	NO	F3	3a	LDV + SOF	NO	2.19E+06	n.d.	17.71
Pt 027^	YES (PegRiba + SMV - SOF)	F2	4d	PTV/r + OMV	YES	9.70E+04	12	n.d.
Pt 028	n.d.	F2	1b	LDV + SOF	YES	n.d.	12	n.d.
Pt 029	YES (PegIFN + TPV + RBV)	F4	1a	SMV + SOF	NO	1.41E+05	12	46.57
Pt 030	Unknown	F4	3a	PTV/r + OMV	YES	6.70E+05	24	n.d.
Pt 031	NO	F4	1a	PTV/r + OMV + DSV	YES	2.79E+06	12	42.57
Pt 032	NO	F4	1a	PTV/r+ OMV + DSV	YES	3.46E+04	24	26.43
Pt 033	NO	F4	1b	SMV + SOF	NO	1.14E+06	12	12.57
Pt 034	NO	F4	1a	SMV + SOF	YES	n.d.	12	n.d.
Pt 035	NO	F4	1b	LDV + SOF	YES	n.d.	12	n.d.
Pt 036	NO	F4	4d	LDV + SOF	YES	n.d.	12	n.d.
Pt 037	NO	F4	3a	DCV + SOF	YES	n.d.	12	n.d.
Pt 038	YES (PegIFN + TPV + RBV)	F4	1a	DCV + SOF	NO	n.d.	24	n.d.
Pt 039	NO	F4	1a	LDV + SOF	YES	n.d.	12	n.d.
Pt 040	NO	F4	3a	LDV + SOF	NO	1.12E+05	24	30.57

Pt 041	n.d.	n.d.	1b	SOF	YES	n.d.	16	n.d.
Pt 042	n.d.	n.d.	4d	PTV/r + OMV	YES	9.30E+06	12	n.d.
Pt 043	n.d.	n.d.	4d	SMV + SOF	YES	7.40E+05	12	n.d.
Pt 044	n.d.	n.d.	1b	PTV/r + OMV + DSV	YES	n.d.	n.d.	n.d.
Pt 045	NO	F1	1b	FDV + DLV	YES	n.d.	12	n.d.
Pt 046	n.d.	n.d.	1b	SMV + SOF	YES	n.d.	n.d.	n.d.
Pt 047	n.d.	n.d.	1b	SMV + SOF	YES	n.d.	n.d.	n.d.
Pt 048	n.d.	F4	1b	LDV + SOF	NO	4.50E+05	12	9.29
Pt 049	n.d.	n.d.	1b	LDV + SOF	NO	4.70E+06	12	10.14
Pt 050	NO	F3	1b	PegIFN lambda + DCV	YES	1.34E+06	n.d.	n.d.
Pt 051	NO	F4	3a	LDV + SOF	NO	8.50E+05	24	24.86
Pt 052	n.d.	F0-F1	1b	FDV + DLV	YES	1.31E+06	48	229.14
Pt 053	NO	F3	1a	LDV + SOF	NO	7.90E+05	8	17.71
Pt 054	NO	F0-F1	1a	SMV + PEG	YES	1.10E+06	24	13.00
Pt 055	n.d.	n.d.	1b	DCV + SOF	NO	n.d.	24	n.d.
Pt 056	NO	F4	1b	SMV + SOF	YES	1.78E+07	12	12.29
Pt 057	n.d.	n.d.	3a	DCV + SOF	NO	n.d.	12	n.d.
Pt 058	n.d.	n.d.	3a	PTV/r + OMV + DSV	NO	n.d.	12	n.d.
Pt 059	NO	n.d.	2j	SOF + PEGINF	YES	7.42E+06	12	48.86
Pt 060	n.d.	n.d.	1b	LDV + SOF	YES	n.d.	n.d.	n.d.
Pt 061	n.d.	n.d.	3a	DCV + SOF	YES	n.d.	12	n.d.
Pt 062	n.d.	n.d.	3a	DCV + SOF	YES	n.d.	12	n.d.
Pt 063	NO	F4	1b	DCV + SOF	NO	6.88E+05	24	14.00
Pt 064	n.d.	F4	1b	LDV + SOF	NO	1.03E+06	12	19.00
Pt 065	NO	F4	3a	LDV + SOF	YES	1.53E+05	24	21.71
Pt 066	n.d.	F4	3a	LDV + SOF	YES	8.00E+05	12	n.d.
Pt 067	NO	F4	1b	DCV + SOF	NO	n.d.	24	n.d.
Pt 068	n.d.	n.d.	1b	SMV + SOF	YES	n.d.	12	16.00
Pt 069	n.d.	n.d.	1b	DCV + SOF	YES	n.d.	12	13.00
Pt 070	n.d.	n.d.	1a	SMV + SOF	YES	n.d.	12	6.43
Pt 071	n.d.	n.d.	1a	LDV + SOF	YES	n.d.	12	10.43
Pt 072	n.d.	n.d.	1a	PTV/r + OMV + DSV	YES	n.d.	24	n.d.
Pt 073	n.d.	F4	4d	SMV + SOF	YES	6.81E+05	12	59.00
Pt 074	n.d.	20KPa	4d	PTV/r + OMV	YES	1.10E+07	n.d.	n.d.
Pt 075	n.d.	n.d.	1b	SMV + DCV	NO	n.d.	24	13.86
Pt 076	n.d.	n.d.	1b	SMV + SOF	YES	n.d.	12	4.00
Pt 077	n.d.	n.d.	4d (69,3%)+1b (30,6%)	LDV + SOF	YES	n.d.	12	13.57
Pt 078	n.d.	n.d.	4d	SMV + SOF	YES	n.d.	12	11.86
Pt 079	NO	F4	3a	SOF	YES	n.d.	24	n.d.
Pt 080	n.d.	n.d.	3a	LDV + SOF	YES	n.d.	24	n.d.
Pt 081	n.d.	n.d.	3a	DCV + SOF	YES	n.d.	24	n.d.
Pt 082	n.d.	n.d.	1b	SMV + SOF	YES	n.d.	24	n.d.
Pt 083	n.d.	n.d.	1b	SMV + SOF	NO	n.d.	12	n.d.
Pt 084	n.d.	n.d.	1b	LDV + SOF	YES	n.d.	12	n.d.

Pt 085	n.d.	F4	3a	PTV/r + OMV	YES	7.50E+04	24	13.00
Pt 086	NO	13KPa	1b	LDV + SOF	NO	3.70E+06	8	11.86
Pt 087	n.d.	n.d.	1b	SMV + SOF	YES	n.d.	12	4.00
Pt 088	YES (PEG-IFN + TPV + RBV)	F3	1b	LDV + SOF	YES	n.d.	12	n.d.
Pt 089	NO	F4	1b	PTV/r + OMV + DSV	YES	n.d.	12	n.d.
Pt 090	NO	F4	1b	SMV + SOF	NO	n.d.	12	n.d.
Pt 091	NO	F4	1b	SMV + SOF	NO	n.d.	12	n.d.
Pt 092	NO	F4	1a	PTV/r + OMV + DSV	YES	n.d.	24	n.d.
Pt 093	n.d.	n.d.	1b	SMV + SOF	YES	n.d.	12	16.14
Pt 094	n.d.	n.d.	1b	SMV + SOF	YES	n.d.	12	13.86
Pt 095	NO	F1	2c	UPF	NO	4.20E+06	8	8.14
Pt 096	NO	F2	1a	PTV/r + OMV + DSV	YES	n.d.	12	n.d.
Pt 097	n.d.	n.d.	1b	SMV + SOF	YES	n.d.	12	11.71
Pt 098	n.d.	n.d.	1b (80%)+1a (19,9%)	SMV + SOF	YES	n.d.	12	n.d.
Pt 099	n.d.	n.d.	1b	SMV + SOF	NO	n.d.	24	n.d.
Pt 100	n.d.	n.d.	1b	SMV + SOF	YES	n.d.	12	n.d.
Pt 101	n.d.	n.d.	1b	SMV + SOF	YES	n.d.	12	6.43
Pt 102	n.d.	n.d.	3a	DCV + SOF	YES	9.20E+05	24	20.86
Pt 103	n.d.	n.d.	3a	DCV + SOF	YES	n.d.	24	14.00
Pt 104	n.d.	F4	3a	DCV + SOF	NO	1.44E+05	24	82.86
Pt 105	NO	F4	1b	PTV/r + OMV + DSV	YES	8.30E+05	12	62.43
Pt 106	NO	F4	1b	LDV + SOF	NO	1.50E+06	12	20.00
Pt 107	NO	F2	1a	LDV + SOF	NO	3.43E+06	12	17.00
Pt 108	n.d.	F1	1a	LDV + SOF	NO	3.45E+06	8	18.71
Pt 109	NO	n.d.	3a	DCV + SOF	NO	4.10E+06	24	20.00
Pt 110	NO	F4	1b	LDV + SOF	YES	1.01E+05	12	23.57
Pt 111	n.d.	F4	1b	LDV + SOF	YES	2.82E+06	12	n.d.
Pt 112	YES (Debio + PEG + RBV)	7,8KPa	1a	SMV + SOF	YES	7.18E+06	12	79.86
Pt 113	n.d.	F4	1b	LDV + SOF	NO	7.49E+05	12	24.71
Pt 114	NO	n.d.	4d	LDV + SOF	NO	3.16E+05	12	14.43
Pt 115	n.d.	F4	1b	SMV + SOF	NO	7.33E+04	12	78.57
Pt 116	n.d.	F4	3a	DCV + SOF	YES	1.26E+05	16	17.43
Pt 117	NO	F4	4d	LDV + SOF	NO	7.43E+04	12	73.71
Pt 118	NO	F4	1a	LDV + SOF	YES	1.79E+05	12	12.00
Pt 119	NO	n.d.	1b	DCV + SOF	NO	1.52E+06	12	31.00
Pt 120	NO	n.d.	1b	LDV + SOF	NO	1.40E+06	12	16.00
Pt 121	NO	48KPa	4d	SMV + SOF	NO	n.d.	n.d.	n.d.
Pt 122	n.d.	F4	1b	PTV/r + OMV + DSV	NO	3.56E+05	12	19.00
Pt 123	NO	F3	1a	LDV + SOF	NO	3.83E+06	12	16.86
Pt 124	NO	F2	3a	DCV + SOF	NO	2.07E+07	12	13.00
Pt 125	n.d.	n.d.	1a	LDV + SOF	NO	1.87E+06	8	29.71
Pt 126	n.d.	F0-F1	3a	DCV + SOF	YES	7.23E+06	12	90.43
Pt 127	NO	F2	1a	LDV + SOF	NO	4.33E+06	8	21.29
Pt 128	n.d.	n.d.	1a	LDV + SOF	NO	9.48E+05	12	56.14

Pt 129	NO	F4	4d	LDV + SOF	YES	3.93E+06	8	8.57
Pt 130	NO	F4	4d	LDV + SOF	YES	1.04E+06	12	7.57
Pt 131	n.d.	n.d.	1b	SMV + DCV	NO	3.31E+05	n.d.	n.d.
Pt 132	NO	F3	1b	SOF	YES	n.d.	15	10.14
Pt 133	NO	F3	1b	LDV + SOF	YES	3.23E+05	24	10.71
Pt 134	NO	F4	1b	SMV + SOF	YES	6.07E+06	12	5.29
Pt 135	NO	F4	1b	SMV + SOF	NO	1.99E+05	12	24.71
Pt 136	YES (LDV + SOF + RBV)	F4	1a	SMV + SOF	YES	1.31E+06	24	15.86
Pt 137	n.d.	F3	3a	DCV + SOF	NO	5.95E+06	12	20.14
Pt 138	NO	n.d.	1b	SMV + SOF	NO	3.61E+05	12	79.86
Pt 139*	Unknown	F3	3a	DCV + SOF	NO	2.60E+05	16?	n.d.
Pt 140	Unknown	n.d.	3a	LDV + SOF	YES	4.80E+06	12	n.d.
Pt 141	NO	F4	1a	LDV + SOF	NO	2.21E+06	12	49.14
Pt 142	n.d.	F4	1a	LDV + SOF	NO	6.00E+05	12	36.86
Pt 143	NO	F2	1a	LDV + SOF	NO	1.39E+06	8	n.d.
Pt 144	n.d.	n.d.	4d	LDV + SOF	YES	n.d.	12	n.d.
Pt 145	NO	F1	1a	PTV/r + OMV + DSV	NO	5.37E+06	12	41.57
Pt 146	NO	F4	4a (98,5%) + 1b (1,5%)	LDV + SOF	NO	1.40E+05	24	23.00
Pt 147	Unknown	F4	1b	DCV + SOF	YES	5.28E+06	12	n.d.
Pt 148	n.d.	n.d.	1b	LDV + SOF	NO	9.83E+05	12	n.d.
Pt 149	n.d.	n.d.	3a	DCV + SOF	NO	n.d.	n.d.	n.d.
Pt 150	n.d.	n.d.	3a	DCV + SOF	NO	n.d.	n.d.	n.d.
Pt 151	n.d.	F3	3a	LDV + SOF	NO	8.16E+06	12	37.86
Pt 152	n.d.	n.d.	1a	LDV + SOF	NO	6.10E+05	24	22.71
Pt 153	n.d.	n.d.	1b	LDV + SOF	YES	n.d.	12	n.d.
Pt 154	NO	F4	3a	DCV + SOF	NO	1.58E+05	24	n.d.
Pt 155	n.d.	F4	1a	LDV + SOF	YES	6.90E+04	n.d.	n.d.
Pt 156	n.d.	n.d.	1b	DCV + IFN	YES	n.d.	n.d.	n.d.
Pt 157	NO	F3	1b	LDV + SOF	NO	1.93E+05	8	14.00
Pt 158	YES (PegIFN + RBV + SMV)	n.d.	4d	PTV/r + OMV	YES	1.38E+05	24	14.43
Pt 159	n.d.	n.d.	4d	LDV + SOF	YES	6.33E+04	12	45.14
Pt 160	n.d.	n.d.	3a	LDV + SOF	NO	4.29E+05	12	n.d.
Pt 161	NO	F2	1b	PTV/r + OMV + DSV	NO	7.02E+05	12	20.14
Pt 162	YES (SMV + SOF)	F4	1a	LDV + SOF	YES	2.60E+06	4	11.14
Pt 163	NO	8,3KPa	3a	PTV/r + OMV + DSV	YES	1.70E+06	12	31.14
Pt 164	NO	10,4KPa	3a	SOF + PEGINF	YES	6.06E+05	12	79.29
Pt 165	YES (IFN + RBV + SOF)	27,4KPa	3a	DCV + SOF	YES	1.96E+06	24	16.00
Pt 166	n.d.	n.d.	2i	SOF	YES	n.d.	n.d.	n.d.
Pt 167	n.d.	n.d.	1b	SMV + SOF	YES	n.d.	n.d.	n.d.
Pt 168	n.d.	n.d.	1b	LDV + SOF	YES	n.d.	n.d.	n.d.
Pt 169	n.d.	n.d.	1b	LDV + SOF	YES	n.d.	n.d.	n.d.
Pt 170	NO	9,8KPa	1a	PTV/r + OMV + DSV	NO	4.85E+06	12	48.71
Pt 171	NO	F4	1l	LDV + SOF	YES	1.09E+06	12	18.00
Pt 172	YES (SMV + SOF + RBV)	F3-F4	4d	LDV + SOF	YES	7.05E+05	24	12.57

Pt 173	NO	F4	1a	PTV/r + OMV + DSV	NO	5.39E+05	12	25.43
Pt 174	n.d.	F4	4d	LDV + SOF	NO	9.66E+05	12	9.86
Pt 175	NO	F2	3a	DCV + SOF	NO	1.87E+06	12	14.00
Pt 176	NO	F3	3a	DCV + SOF	NO	7.00E+06	12	44.86
Pt 177	n.d.	n.d.	3a	DCV + SOF	NO	1.33E+04	24	75.14
Pt 178	NO	F4	1a	LDV + SOF	NO	4.49E+06	12	37.00
Pt 179	n.d.	n.d.	1a	LDV + SOF	NO	2.03E+04	12	19.00
Pt 180	NO	F2	4d	PTV/r + OMV	YES	1.40E+05	12	13.71
Pt 181	NO	F3	1a	LDV + SOF	NO	1.30E+07	12	12.71
Pt 182	n.d.	F4	1b	LDV + SOF	NO	1.23E+06	12	24.00
Pt 183	NO	n.d.	4d (96,7%) + 3a (3,3%)	PTV/r + OMV	YES	1.59E+06	12	3.43
Pt 184	n.d.	F3	1a	SMV + DCV	YES	1.41E+06	24	57.43
Pt 185	NO	F2	1a	LDV + SOF	NO	2.54E+04	8	22.00
Pt 186	NO	F4	1b	LDV + SOF	NO	3.44E+05	12	13.71
Pt 187	NO	F4	1b	LDV + SOF	NO	1.57E+06	24	0.43
Pt 188	NO	F3	1b	LDV + SOF	NO	6.57E+05	12	12.71
Pt 189	n.d.	n.d.	4d	LDV + SOF	YES	n.d.	n.d.	n.d.
Pt 190	n.d.	n.d.	1b	GLE + PIB	NO	n.d.	n.d.	n.d.
Pt 191	n.d.	n.d.	4d	PTV/r + OMV	YES	4.03E+06	12	34.00
Pt 192	n.d.	n.d.	1a	LDV + SOF	NO	n.d.	12	n.d.
Pt 193	n.d.	F2	1a	LDV + SOF	NO	1.72E+06	8	12.29
Pt 194	YES (PTV + OMV + DSV + RBV)	n.d.	4d	LDV + SOF	YES	6.24E+04	n.d.	n.d.
Pt 195	NO	n.d.	1b	SMV + SOF	YES	1.64E+06	12	100.14
Pt 196	NO	F2	1b	LDV + SOF	NO	4.50E+06	8	14.14
Pt 197	n.d.	n.d.	4d	GZR + EBR	YES	1.45E+06	12	106.71
Pt 198	NO	F1	1a	LDV + SOF	NO	3.80E+06	8	14.00
Pt 199	NO	F4	1a	LDV + SOF	NO	4.52E+04	12	5.71
Pt 200	NO	F4	3a	DCV + SOF	YES	3.48E+05	12	2.71
Pt 201	n.d.	n.d.	3a	DCV + SOF	YES	3.22E+07	24	34.71
Pt 202	YES (LDV + SOF + RBV)	n.d.	4d	PTV/r + OMV	YES	2.23E+06	12	3.86
Pt 203	NO	Unknown	2j	SOF	YES	3.52E+05	16	35.57
Pt 204	NO	F3	1a	LDV + SOF	NO	1.00E+07	12	27.57
Pt 205	YES (SMV + SOF)	F4	1a	DCV + SOF	NO	6.32E+05	24	18.86
Pt 206	n.d.	F4	1b	LDV + SOF	NO	1.26E+06	12	6.86
Pt 207^	YES (PTV + OMV)	F3	4d	LDV + SOF	YES	3.43E+05	24	0.86
Pt 208	NO	F1	1a	PTV/r + OMV + DSV	NO	n.d.	12	n.d.
Pt 209	NO	F4	1a	LDV + SOF	YES	n.d.	12	n.d.
Pt 210	NO	F4	1a	LDV + SOF	YES	n.d.	12	n.d.
Pt 211	NO	F1	4d	PTV/r + OMV	YES	n.d.	12	n.d.
Pt 212	NO	F1	1a	PTV/r + OMV	NO	n.d.	12	n.d.
Pt 213	YES (IFN _{peg} /RBV + TPV)	F3	1b	SMV + SOF	NO	n.d.	12	n.d.
Pt 214	NO	F4	3a	DCV + SOF	NO	n.d.	24	n.d.
Pt 215	NO	F4	3a	DCV + SOF	NO	n.d.	24	n.d.
Pt 216	YES (SMV + SOF)	F3	1b	LDV + SOF	NO	n.d.	12	n.d.

Pt 217	n.d.	n.d.	1b	LDV + SOF	NO	8.73E+05	12	79.86
Pt 218	NO	n.d.	1b	SOF	YES	1.54E+05	4	6.57
Pt 219	n.d.	F0-F1	1a	PTV/r + OMV	YES	1.17E+06	12	1.29
Pt 220*	YES (DCV + SOF)	n.d.	3a	GZR + EBR + SOF	NO	7.00E+07	n.d.	n.d.

^ Patient who has failed two different treatments.

* Patient who has failed two different treatments.

n.d. no data.

Table S2.

Patient	Amplicon	Mutation	Results MiSeq		Results 454 GS-Junior	
			Reads	Frequency (%)	Reads	Frequency (%)
Pt 005	7952.8389	E131D	26948	100	8991	100
		V147I	481	1.8	126	1.4
		V167A	620	2.3	188	2.1
		Y195H	873	3.2	271	3.0
		S213C	26948	100	8991	100
		A218S	26948	100	8991	100
		S231N	26708	99.1	8908	99.1
	S231D	-	-	83	0.9	
	8142.8584	Y195H	938	3.1	314	3.1
		S213C	29784	100	10225	100
		A218S	29784	100	10225	100
		S231N	29523	99.1	10104	98.8
		S231D	-	-	121	1.2
		C279R	1074	3.6	371	3.6
S300T		29784	100	10179	99.6	

Table S3.1

		NS5A								
	Pt	R30Q (%)	L31I (%)	L31M (%)	L31V (%)	Y93H (%)	R30Q+Y93H (%)	L31I+Y93H (%)	L31M+Y93H (%) ¹	L31V+Y93H (%) ²
	011	-	21.6	-	58.8	100	-	21.6	-	58.8
	012	-	-	100	-	100	-	-	100	-
	019	-	-	100	-	100	-	-	100	-
	021	-	-	100	-	100	-	-	100	-
	028	-	100	-	-	100	-	100	-	-
	035	100	-	-	-	99.7	99.7	-	-	-
	048	-	-	100	-	98.1	-	-	98.1	-
	049	100	-	-	-	100	100	-	-	-
	060	-	-	99.6	-	94.8	-	-	89.3	-
	064	-	-	100	-	100	-	-	100	-
LDV+SOE	086	-	89.7	-	2.2	100	-	89.7	-	2.2
	088	-	-	100	-	98.7	-	-	98.7	-
	110	-	22.7	-	-	68	-	13.1	-	-
	111	100	-	100	-	100	100	-	100	-
	113	-	100	-	-	100	-	100	-	-
	120	-	-	1.1	97.3	4.2	-	-	0.42	2.91
	157	-	100	-	-	100	-	100	-	-
	168	-	-	100	-	98	-	-	98	-
	169	-	-	100	-	100	-	-	100	-
	187	-	-	100	-	100	-	-	100	-
	196	100	-	-	-	100	100	-	-	-
	216	-	-	72.4	27.6	100	-	-	72.4	27.6
	Pt	R30Q (%)	L31I (%)	L31M (%)	L31V (%)	Y93H (%)	R30Q+Y93H (%)	L31I+Y93H (%)	L31M+Y93H (%) ¹	L31V+Y93H (%) ²
DCV+SOE	055	-	100	-	-	100	-	100	-	-
	063	-	-	100	-	100	-	-	100	-
	067	-	-	-	98.6	97.1	-	-	-	88.3
	069	-	-	99	-	94.5	-	-	89.9	-
	147	-	-	93.1	6.9	100	-	-	93.1	6.9

¹ L31M + Y93H confers 4227 fold-increase resistance to daclatasvir *in vitro*.

² L31V + Y93H confers 5425 fold-increase resistance to daclatasvir *in vitro*.

Table S3.2

NS5B				
	Pt	L159F (%)	C316N (%)	L159F+C316N (%)¹
LDV+SOF	011	100	100	100
	021	100	100	100
	035	99.5	99.2	≈ 99
	049	99.5	99.4	≈ 99
	064	99.3	99.3	≈ 99
	084	100	99.5	99.5
	086	100	100	100
	110	99.5	98.2	≈ 98
	111	99.3	99	≈ 99
	120	100	100	100
	133	99.6	99.6	≈ 99
	153	99.4	99.5	≈ 99
	157	99.5	100	99.5
	186	99.4	99.6	≈ 99
	196	99.6	100	99.6
	206	99.5	100	99.5
216	99.5	100	99.5	
DCV+SOF	Pt	L159F (%)	C316N (%)	L159F+C316N (%)
	055	100	100	100
	067	100	100	100
	069	99.5	100	99.5

¹ As L159F and C316N were sequenced in different amplicons, in cases of patients who carried both RAS at frequency below 100%, the frequency of genomes carried L159F+C316N combined among viral population reported here is just approximation of the real number.

Table S3.3

SMV+SOF					
NS3	Pt	Q80R (%)	D168E (%)	Q80R+D168E (%) ¹	
	005	99.4	100	99.4	
	007	100	100	100	
	082	6.6	100	6.6	
	083	82.1	80	82.1	
	087	100	100	100	
	Pt	R155Q (%)	D168A (%)	R155Q+D168A (%)	
	090	29.3	51.5	19.8	
	094	14.9	57.7	10.4	
	138	1.5	1.5	1.5	
	167	3.8	21.3	2.5	
	NS5B	Pt	L159F (%)	C316N (%)	L159F+C316N (%) ²
		003	100	99.4	99.4
015		100	99.1	99.1	
033		100	100	100	
046		99.3	100	99.3	
056		100	99.6	99.6	
068		99.4	99.5	≈ 99	
082		100	100	100	
087		99.6	100	99.6	
090		98.7	99.6	≈ 98	
115		99.5	100	99.5	
134		99.2	98.9	≈ 98	
138		94.6	99.4	≈ 94	
167		99.5	100	99.5	
195		99.5	100	99.5	
213	99.4	100	99.4		

¹ Q80R + D168E confers 418 fold-increase resistance to simeprevir *in vitro*.

² As L159F and C316N were sequenced in different amplicons, in cases of patients who carried both RAS at frequency below 100%, the frequency of genomes carried L159F+C316N combined among viral population reported here is just approximation of the real number.

Table S3.4

		PTV/r+OMV+DSV				
	Pt	Y56H (%)	D168V (%)	Y56H+D168V (%) ¹		
NS3	044	97.7	100	97.7		
	122	100	100	100		
	161	3.9	3.7	0.66		
		PTV/r+OMV+DSV				
	Pt	R30Q (%)	Y93H (%)	R30Q+Y93H (%)		
NS5A	105	100	100	100		
	122	100	100	100		
	161	100	100	100		
		PTV/r+OMV+DSV				
	Pt	L159F (%)	C316N (%)	S556G (%)	L159F+C316N (%) ²	L159F+C316N+S556G (%) ³
NS5B	017	100	99.5	100	-	99.5
	018	99.6	99.1	100	-	≈ 99
	044	99.3	100	99.1	-	≈ 99
	089	99.4	99.6	-	≈ 99	-
	161	100	100	-	100	-

¹ Y56H + D168V confers 2472 fold-increase resistance to paritaprevir *in vitro*.

² As L159F and C316N were sequenced in different amplicons, in cases of patients who carried both RAS at frequency below 100%, the frequency of genomes carried L159F+C316N combined among viral population reported here is just approximation of the real number.

³ AS each RAS were sequenced in different amplicons, the real frequency of combinations within viral population is only an estimation about

Complejo Hospitalario Univ. A Coruña
Complejo Hospitalario Univ. de Pontevedra
Complejo Hospitalario Univ. de Ourense
Xerencia de Xestión Integrada de Ourense


Hosp. Univ. Central de Asturias

Hosp. Univ. Marqués de Valdecilla

Hosp. Univ. Donosti
Hosp. de Galdakao

Hosp. General de La Rioja

Hosp. Univ. La Fe de Valencia
Hosp. Univ. General de Valencia



Hosp. Univ. San Cecilio

Hosp. Univ. de Burgos

Hosp. 12 de Octubre
Hosp. La Princesa
Hosp. Univ. La Paz
Hosp. Univ. Puerta de Hierro
Hosp. Univ. Ramón y Cajal

Hosp. Virgen de la Salud

Hosp. Univ. de Canarias
Hosp. Univ. Dr. Negrin

Hosp. Univ. Vall d'Hebron
Hosp. Univ. de Bellvitge
Hosp. Univ. Clinic
Hosp. Univ. Germans Trias i Pujol
Hosp. de la Santa Creu i Sant Pau
Hosp. Parc de la Salut Mar
Hosp. Univ. Mutua de Terrasa
Hosp. Univ. Dr. Josep Trueta
Hosp. Univ. Arnau de Vilanova de Lleida
Hosp. Sant Pau i Santa Tecla
Hosp. Univ. Joan XXIII
Hosp. Comarcal Sant Jaume de Calella
Hosp. General de Granollers
Hosp. de Mataró
Hosp. Santa María de Lleida
Hosp. Comarcal de Blanes
Hosp. Consorci Sanitari de Terrasa
Laboratori Territorial de Girona

*** Vall d'Hebron Institut de Recerca
(Barcelona)**

Ledipasvir (LDV) + Sofosbuvir (SOF)

Subtype

G1b (N=35)



G1a (N=28)



G4d (N=13)



G3a (N=9)



Simeprevir (SMV) + Sofosbuvir (SOF)

Subtype

G1b (N=28)



G1a (N=6)



G4d (N=4)



Daclatasvir (DCV) + Sofosbuvir (SOF)

Subtype

G1b (N=6)



G3a (N=27)



Paritaprevir / ritonavir (PTV/r) + Ombitasvir (OMV) + Dasabuvir (DSV)

Subtype

G1b (N=7)



G1a (N=10)



G3a (N=3)

